EarliPoint Health Launches Skill Illustrator™ to Help Providers Translate Assessment Data into Actionable Developmental Insights.

Read Release →

Questions to Ask Your ABA Provider About Measuring Progress

On This Page

Choosing an ABA provider is one decision. Knowing whether therapy is actually helping your child is an ongoing one that often depends on how the practice measures progress.

Most parents are never told what to ask. This guide gives you a practical set of questions, what good answers sound like, and a few gentle flags to watch for.

Why Measurement Is the Question That Matters

ABA programs generate a lot of paperwork — session notes, graphs, goal lists. But volume isn’t the same as measurement. What you want to understand is simple: how will this team know, and show you, that your child is making meaningful progress — and how will they know when something needs to change? Providers who measure well tend to welcome these questions. That reaction itself is useful information.

The Questions

1. “Which assessments will you use, and when will you repeat them?”

A quality program names specific tools and a schedule. Common answers include skills assessments like the ABLLS-R or VB-MAPP (which guide what to teach) and standardized measures like the Vineland-3 (which compares your child’s everyday functioning to age expectations). Reassessment on a regular cycle — commonly around every six months — is standard practice.

Gentle flag: vague answers (“we track goals continuously”) with no named assessment or reassessment schedule.

2. “What does this assessment measure — skills, behavior, or development?”

Different tools answer different questions, and a good clinician can explain the difference in plain language: a skills assessment shows what your child can do and what comes next; an adaptive measure shows how daily functioning compares to same-age peers; and some practices add objective, device-based developmental measurement to complement those. If a provider can’t explain what a tool does, they may struggle to explain your child’s results.

3. “How much of the data comes from what I report, versus direct measurement of my child?”

This is the question few parents know to ask. Some widely used measures are based substantially on parent interviews or questionnaires — valuable, but dependent on recall and perspective. Others are based on direct observation or direct measurement of the child. A thoughtful answer acknowledges the mix and explains how the team balances it.

4. “How will you share results with me — and how often?”

You should expect plain-language reviews of progress data at regular intervals, not just an annual report. Ask to see an example progress summary (with another family’s information removed). Practices that communicate well usually have one ready.

5. “What happens if the data shows my child isn’t progressing?”

The best answer is specific: the team reviews the program, adjusts goals or teaching strategies, and tells you what changed and why. Measurement is only useful if it drives decisions.

6. “Who reviews the data, and how often?”

You’re listening for regular oversight by the supervising BCBA — not data that accumulates unreviewed.

7. “Will the same tools be used each time, so results are comparable?”

Progress is a comparison over time. Switching instruments midstream, or having different people score the same instrument differently, makes change harder to interpret. Consistency of measurement across reassessments is a mark of a careful program.

A Note on Objective Measurement

Historically, obtaining objective measures of developmental progress was challenging to do routinely. While ABA programs have long relied on careful measurement of specific skills and behaviors, assessing broader developmental change often required lengthy standardized evaluations conducted by specialists such as psychologists, neuropsychologists, or speech-language pathologists.

These assessments provide valuable information, but the time, cost, and resources required make frequent reassessment impractical for many families and providers. New technology-based approaches are beginning to make objective, biomarker-informed measurement more accessible. These tools offer the opportunity to complement traditional behavioral data with additional information about developmental progress over time, helping providers evaluate not only whether a child is learning specific skills, but also whether interventions are supporting meaningful changes in developmental functioning.

One example of this emerging approach is the EarliPoint System, an FDA-cleared medical device indicated for use as a tool to aid qualified clinicians in the diagnosis and assessment of ASD in children 16 to 95 months old who are at risk based on concerns shared by a parent, caregiver, or healthcare provider. During an assessment, your child simply watches short videos of social scenes while the device measures looking behavior. There are no tasks to perform. Practices that incorporate objective developmental measurement have an additional way to monitor whether treatment plans are supporting meaningful developmental progress, alongside traditional clinical observation, caregiver input, and skill-based assessments.

You don’t need to insist on any particular tool. But asking whether a practice includes any objective measure of your child’s development is a fair and increasingly common question.

Frequently asked questions

How often should my child be reassessed in ABA?

Formal reassessment commonly happens around every six months, though the schedule varies by program and funder requirements. Ongoing session data should be reviewed much more frequently by the supervising clinician.

What’s the difference between session data and an assessment?

Session data tracks performance on specific program targets day to day. Formal assessments step back and measure broader skills or development at a point in time, so progress can be compared across months or years.

Should I be able to see my child’s progress data?

Yes. You’re entitled to understand your child’s progress, and quality providers proactively review data with families in plain language.

What if I don’t understand the graphs and scores?

Ask. Translating results into plain language is part of the provider’s job — and a provider’s willingness to do so is a good indicator of overall quality.

Cheryl Tierney, MD, MPH

Chief Medical Officer

Developmental pediatrician, public health advocate, and Chief Medical Officer at EarliPoint Health. Cheryl blends scientific curiosity with real-world passion — as a physician, professor, and mom, she’s committed to turning early autism research into better care and support for families.

Cheryl Tierney, MD, MPH

Chief Medical Officer

Cheryl serves as EarliPoint’s Chief Medical Officer, helping advance early autism research into more accessible care and support for families.

See how EarliPoint fits seamlessly into your clinical workflow.

Jamie Pagliaro brings over two decades of leadership in autism and behavioral health to his role as President and CEO of EarliPoint. Most recently, he served as Chief Operating Officer at Rethink, a leading SaaS provider supporting individuals with autism and developmental disabilities. Under his leadership, Rethink’s behavioral health division became the company’s largest business unit, serving thousands of clinicians and driving scalable, tech-enabled care delivery.

Earlier in his career, Jamie was Executive Director of the New York Center for Autism Charter School, the first public charter school in New York State dedicated to children with autism. At EarliPoint, he leads the company’s mission to bring breakthrough science to the front lines of care—empowering providers, families, and health systems with earlier answers and better outcomes.

Jamie Pagliaro

President & Chief Executive Officer

Dr. Ami Klin is a globally recognized leader in autism research and early detection. As Director of the Marcus Autism Center and Division Chief of Autism and Developmental Disabilities at Emory University School of Medicine, he has dedicated his career to understanding how young children engage with the social world—and how subtle disruptions in attention can signal developmental differences. His pioneering work in eye-tracking science led to the development of EarliPoint™ Evaluation, the first FDA-authorized tool to objectively assess autism in children as young as 16 months.
At EarliPoint, Dr. Klin drives clinical strategy and innovation, ensuring that families and clinicians worldwide have access to timely, science-based insights that enable earlier, more personalized intervention. His career reflects a deep commitment to transforming how society supports children with autism—starting with the earliest signs.

Ami Klin, PhD

Chief Clinical Officer & Co‑Founder